2-amino-3-methyl-6-phenyl-4(3H)-pyrimidinoene | 92519-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-amino-3-methyl-6-phenyl-4(3H)-pyrimidinoene
• 英文别名: 2-amino-3-methyl-6-phenyl-3H-pyrimidin-4-one；2-Amino-3-methyl-6-phenyl-4-pyrimidinone；2-amino-3-methyl-6-phenylpyrimidin-4-one
• CAS: 92519-10-3
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: YSIQOXUHLACNPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-3-methyl-6-phenyl-4(3H)-pyrimidinoene 生成 2-Amino-5-iodo-3-methyl-6-phenylpyrimidin-4(3H)-one
  参考文献：
  名称：

  VIERENGA, W.;SKULNICK, H. I.

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-4-羟基-6-苯基嘧啶 、 碘甲烷 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 96.0h， 生成 2-amino-3-methyl-6-phenyl-4(3H)-pyrimidinoene
  参考文献：
  名称：

  [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSES HETEROCYCLIQUES SUBSTITUES ET LEURS METHODES D'UTILISATION

  摘要：

  公开号：

  WO2005070932A3

文献信息

• [EN] SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES AMINO SUBSTITUES ET UTILISATION DE CES COMPOSE
  申请人：ASTRAZENECA AB

  公开号：WO2006041404A1

  公开（公告）日：2006-04-20

  This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  这项发明涉及具有结构式Ia或结构式Ib的新化合物：Ia Ib及其药用可接受的盐、互变异构体或体内可水解的前体，以及其组合物和使用方法。这些新化合物提供了治疗或预防与Aβ相关的病理学，如认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症的方法。
• Substituted heterocyclic compounds and methods of use
  申请人：Frohn J. Michael

  公开号：US20050187223A1

  公开（公告）日：2005-08-25

  The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

  本发明涉及嘧啶酮和吡啶酮及其衍生物以及其药学上可接受的盐。还包括一种治疗炎症、类风湿性关节炎、帕吉特氏病、骨质疏松症、多发性骨髓瘤、葡萄膜炎、急性或慢性髓性白血病、胰岛素β细胞破坏、骨关节炎、类风湿脊柱炎、痛风性关节炎、炎症性肠病、成人呼吸窘迫综合症（ARDS）、牛皮癣、克罗恩病、过敏性鼻炎、溃疡性结肠炎、过敏性反应、接触性皮炎、哮喘、肌肉退化、消瘦症、Reiter综合征、1型糖尿病、2型糖尿病、骨吸收疾病、移植物抗宿主反应、阿尔茨海默病、中风、心肌梗塞、缺血再灌注损伤、动脉粥样硬化、脑外伤、多发性硬化症、脑疟疾、败血症、脓毒性休克综合征、发热、HIV-1、HIV-2、HIV-3、巨细胞病毒（CMV）、流感、腺病毒、疱疹病毒或带状疱疹感染的哺乳动物的方法，包括给予上述化合物的有效量。
• Novel compounds and process for treating hypertension
  申请人：The Upjohn Company

  公开号：US04593096A1

  公开（公告）日：1986-06-03

  A process for treating hypertension comprising the systemic administering to a hypertensive subject or a novel compound of the formula: ##STR1## wherein X is alkyl of from 1 to 3 carbon atoms, inclusive, or alkenyl of from 3 to 5 carbon atoms, inclusive. R.sub.1 is --NH.sub.2. R.sub.2 is chloro, bromo, or iodo. R.sub.3 is hydrogen or fluorine. R.sub.4 is hydrogen or fluorine, and R.sub.5 is hydrogen, fluorine, or CH.sub.3 ; or salt thereof, in association with a pharmaceutical carrier. The amount administered is from 0.1 mg to 400 mg/kg of body weight, dosage unit form and dosage amounts disclosed.

  一种治疗高血压的方法，包括将化合物按照以下公式系统地注射给高血压患者：##STR1## 其中，X是1至3个碳原子的烷基，包括或者3至5个碳原子的烯基。R.sub.1是--NH.sub.2。R.sub.2是氯、溴或碘。R.sub.3是氢或氟。R.sub.4是氢或氟，R.sub.5是氢、氟或CH.sub.3；或其盐，与药物载体相关联。所施用的量为0.1毫克至400毫克/千克体重，剂量单位形式和剂量量披露。
• Substituted Amino-Compounds and Uses Thereof
  申请人：Albert Jeffrey Scott

  公开号：US20090221579A1

  公开（公告）日：2009-09-03

  This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有结构式Ia或式Ib的新化合物：Ia Ib及其药学上可接受的盐、互变异构体或体内水解前体，以及其使用的组合物和方法。这些新化合物提供了治疗或预防与Aβ相关的病理学，如认知障碍、阿尔茨海默病、神经退行性和痴呆症的方法。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES ET LEURS METHODES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2005070932A3

  公开（公告）日：2005-10-27